<DOC>
	<DOC>NCT00630656</DOC>
	<brief_summary>Study will evaluate the safety and potential benefit of recombinant human talactoferrin as an addition to the standard care of severe sepsis.</brief_summary>
	<brief_title>Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Age greater than or equal to 18 years Onset of severe sepsis within the previous 24 hours Must be receiving antibiotic therapy Informed consent form signed by patient, legal nextofkin or legal guardian Able to take medication by mouth or feeding tube Receipt of investigational medication within 4 weeks prior to participation in the study Pregnant or breastfeeding Severe congestive heart failure Known severe HIV infection Presence of severe burns Patients on high dose immunosuppressants Patients whose death is considered imminent Patients whose life expectancy for concurrent illness is less than 6 months Severe hypoxic encephalopathy or persistent vegetative state Severe liver disease Patient, legal representative or patient's primary physician not committed to providing full, aggressive life support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>sepsis</keyword>
	<keyword>talactoferrin</keyword>
	<keyword>lactoferrin</keyword>
	<keyword>recombinant human lactoferrin</keyword>
</DOC>